Target intelligence / Profile preview

T cell receptor alpha joining 54 (TRAJ54)

Target
TRAJ54
Molecular classification
Other (Immunoglobulin gene segment; part of the T cell receptor alpha locus, not a standalone protein or receptor)
01

Overview

T cell receptor alpha joining 54 (TRAJ54) is a **gene segment** within the T cell receptor alpha (TRA) locus. It encodes a joining (J) segment that participates in the V(J) recombination process required to generate the variable region of the T cell receptor alpha chain on αβ T cells[3][7]. The TRAJ54 segment does not encode a full-length receptor but, along with variable (V) and constant (C) segments, contributes to the **antigen recognition diversity** of T cell receptors by enabling different combinations through somatic recombination during T cell development[3][7]. TRAJ54 itself is **not a protein or therapeutic target** and does not function independently as a receptor; rather, it is one of many immunoglobulin gene segments essential for the overall function of T cell receptors in antigen recognition and adaptive immunity[3][7]. **Key context:** - TRAJ54 is one of many TRAJ (joining) gene segments that are recombined with TRAV (variable) segments to form the TCR alpha chain's variable region[3][7]. - T cell receptors, as a complex, are fundamental in recognizing antigens presented by major histocompatibility complex (MHC) on antigen-presenting cells, triggering adaptive immune responses[4][7][5]. - Individual TRAJ segments are *not* standalone biological or pharmacological entities and are not described as drug targets in biomedical literature.

Other names
TRAJ54
02

Mechanism of action

Null (Not a receptor or enzyme with a pharmacological mechanism)

03

Biological functions

Null (Does not encode a functional receptor or protein on its own; contributes to the diversity of the T cell receptor alpha chain through genetic recombination)
04

Disease associations

Null (Not directly implicated as a disease target; aberrations may contribute to altered TCR diversity, but not established as a disease driver)
05

Safety considerations

Null
06

Interacting drugs

Null (No direct drug interactions; not itself a protein drug target)
07

Biomarkers

Null

Beyond the preview

Go deeper on T cell receptor alpha joining 54 (TRAJ54).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on T cell receptor alpha joining 54 (TRAJ54).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call